Invesco Ltd. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 508,069 shares of the specialty pharmaceutical company's stock after buying an additional 22,027 shares during the period. Invesco Ltd. owned 0.92% of Supernus Pharmaceuticals worth $18,372,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in SUPN. Barclays PLC raised its stake in Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock valued at $3,393,000 after acquiring an additional 51,005 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock worth $46,218,000 after purchasing an additional 74,438 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 7.6% during the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after purchasing an additional 2,121 shares during the period. Empowered Funds LLC purchased a new position in Supernus Pharmaceuticals in the 4th quarter valued at $1,498,000. Finally, Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares during the period.
Supernus Pharmaceuticals Stock Performance
Supernus Pharmaceuticals stock traded up $0.22 during midday trading on Thursday, reaching $31.06. The company's stock had a trading volume of 61,202 shares, compared to its average volume of 566,518. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The stock's 50 day simple moving average is $32.25 and its 200 day simple moving average is $34.98. The firm has a market capitalization of $1.73 billion, a PE ratio of 29.03 and a beta of 0.90.
Insiders Place Their Bets
In other news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several analysts have recently commented on SUPN shares. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.
View Our Latest Research Report on Supernus Pharmaceuticals
About Supernus Pharmaceuticals
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Further Reading
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
